Pharmacogenetic of Doxorubicin in HCC. - Trial NCT06313047
Access comprehensive clinical trial information for NCT06313047 through Pure Global AI's free database. This phase not specified trial is sponsored by Rehab Werida and is currently Completed. The study focuses on Hepatocellular Carcinoma. Target enrollment is 81 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Rehab Werida
Damanhour University
Timeline & Enrollment
N/A
Jan 01, 2021
Dec 30, 2023
Primary Outcome
GSTP1,CYP2B6
Summary
The study included 81 HCC patients, both male and female. Prior to being assessed for
 eligibility, each recruited patient with HCC received a comprehensive review of their medical
 history, physical status, and laboratory results. Every research participant take part in the
 experiment and provided written informed consent.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06313047
Non-Device Trial